Haffner, Michael C.
Zwart, Wilbert
Roudier, Martine P.
True, Lawrence D.
Nelson, William G.
Epstein, Jonathan I.
De Marzo, Angelo M.
Nelson, Peter S.
Yegnasubramanian, Srinivasan http://orcid.org/0000-0003-0744-6606
Article History
Accepted: 5 November 2020
First Online: 16 December 2020
Competing interests
: S.Y., W.G.N. and A.M.D.M. are paid consultants to and received sponsored research funding from Cepheid. S.Y. and W.G.N. are co-inventors of intellectual property describing the use of DNA methylation changes as prostate cancer biomarkers and are eligible to earn royalties related to the future sale of any products using those technologies. S.Y. and A.M.D.M. receive sponsored research funding from Janssen. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. The other authors declare no competing interests.